3.57
-0.195(-5.19%)
Currency In USD
| Previous Close | 3.76 |
| Open | 3.73 |
| Day High | 3.73 |
| Day Low | 3.55 |
| 52-Week High | 4.6 |
| 52-Week Low | 1.35 |
| Volume | 745,252.66 |
| Average Volume | 1.45M |
| Market Cap | 213.72M |
| PE | -4.63 |
| EPS | -0.77 |
| Moving Average 50 Days | 3.51 |
| Moving Average 200 Days | 2.66 |
| Change | -0.2 |
Eledon Pharmaceuticals Announces Orphan Drug Designation Granted to Tegoprubart for the Prevention of Allograft Rejection in Liver Transplantation
GlobeNewswire Inc.
Mar 10, 2026 11:00 AM GMT
IRVINE, Calif., March 10, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN) today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to tegoprubart for the prevention of allo
Eledon Pharmaceuticals to Participate in Leerink Partners 2026 Global Healthcare Conference
GlobeNewswire Inc.
Mar 04, 2026 9:05 PM GMT
IRVINE, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that David-Alexandre C. Gros, M.D., Chief Executive Officer, and Steven Perrin, Ph.D., President and Chief Scientific Officer,
Eledon Pharmaceuticals to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
GlobeNewswire Inc.
Feb 05, 2026 9:10 PM GMT
IRVINE, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (Nasdaq: ELDN) today announced that Steven Perrin, Ph.D., President and Chief Scientific Officer will participate in a fireside chat at the upcoming Guggenhei